Precision Therapeutics, Inc. Releases Data Determining the Clinical Use of ChemoFx® in Helping to Select Treatment for Patients with Cervical Cancer
5/31/2012 10:27:01 AM
PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. The study, titled, In Vitro Chemoresponse Assay for Patients with Cervical Cancer, reports the results of ChemoFx® testing in primary, metastatic or recurrent cervical cancer. A total of 273 specimens were evaluable for response to single chemotherapeutic agents carboplatin, cisplatin, paclitaxel, docetaxel, epirubicin, fluorouracil, ifosfamide, irinotecan, topotecan and vinorelbine. Doublets tested included carboplatin/paclitaxel and cisplatin/topotecan.